AMPHASTAR PHARMACEUTICALS IN (AMPH)

US03209R1032 - Common Stock

40.45  +0.67 (+1.68%)

After market: 40.45 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (6/21/2024, 7:00:00 PM)

After market: 40.45 0 (0%)

40.45

+0.67 (+1.68%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-33.6%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.98B
Shares
PE10.87
Fwd PE9.06
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AMPH Daily chart

Company Profile

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 1,615 full-time employees. The company went IPO on 2014-06-25. The firm is focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (API) products. The company operates through two segments: finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Primatene Mist is an epinephrine inhalation product, which is indicated for the temporary relief of mild symptoms of intermittent asthma. Its portfolio also includes BAQSIMI (BAK-see-mee), which is used to treat very low blood sugar in people with diabetes ages 4 years and above.

Company Info

AMPHASTAR PHARMACEUTICALS IN

11570 6th St

Rancho Cucamonga CALIFORNIA 91730

P: 19099809484

CEO: Jack Y. Zhang

Employees: 1615

Website: https://amphastar.com/

AMPH News

News Image8 days ago - NAIC-BetterInvestingBetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC

/PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:...

ChartMill News Image17 days ago - ChartmillWhy the growth investor may take a look at NASDAQ:AMPH.

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article.

News Imagea month ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Imagea month ago - InvestorPlaceAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Imagea month ago - BusinessInsiderAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...

News Image2 months ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)

AMPH Twits

Here you can normally see the latest stock twits on AMPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example